EXXUA has been approved for treatment.
Fabre-Kramer Pharmaceuticals announced that the FDA has approved its treatment of major depressive disorder in adults.
In a press release, the company wrote that Exxua is the first antidepressant to be approved with a novel mechanism of action and is able to selectively target the serotonin 1A receptor.
"Exxua represents an important milestone in the treatment of MDD, a serious and debilitating condition that affects millions of people worldwide," said Stephen Kramer, M.D., CEO of Fabre-Kramer in a press release. "There is value in providing prescribers and patients with a wide range of effective options for use in clinical practice. We are proud to bring this innovative therapy to patients who need a new option to manage their depression and improve their quality of life."
According to Fabre-Kramer, Exxua is expected to be available in pharmacies starting in early 2024.
(Sept. 28, 2023); Fabre-Kramer Pharmaceuticals; Fabre-Kramer Pharmaceuticals Announces FDA Approval of EXXUA™, the First and Only Oral Selective 5HT1a Receptor Agonist for the Treatment of Major Depressive Disorder in Adults; https://www.prnewswire.com/news-releases/fabre-kramer-pharmaceuticals-announces-fda-approval-of-exxua-the-first-and-only-oral-selective-5ht1a-receptor-agonist-for-the-treatment-of-major-depressive-disorder-in-adults-301941467.html
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.